A Phase 3, Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Immune Response and Safety of the Herpes Zoster Subunit Vaccine When Administered Intramuscularly on a 2-dose Schedule in Adults Aged 50 Years and Older in India
Latest Information Update: 22 May 2025
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 27 Sep 2022 Planned primary completion date changed from 29 Nov 2022 to 28 Nov 2022.
- 27 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2022 Planned primary completion date changed from 5 Oct 2022 to 29 Nov 2022.